Risdawaty Gil-Salas Ahmad

🌏 Singapore a home to global pharma and biotech leaders! Singapore continues to position itself as one of the strongest global hubs for automation engineers in the pharmaceutical and biotech industry. 😁 From speaking with the market daily, I see first hand how quickly opportunities here are expanding. The country has become a key base for global pharma giants and CDMOs, driving demand for DeltaV, 800xA, PCS7, and MES engineers who can support large-scale projects across GMP manufacturing. Recently, I’ve helped DeltaV engineers relocate to Singapore to support major pharmaceutical projects & the feedback has been incredible. For contractors especially, Singapore offers the chance to work across multiple projects with leading end clients, building both technical expertise and international experience. With strong government support, heavy investment in biologics, and continuous growth in digital manufacturing initiatives, the opportunities here for automation talent will only continue to grow. ✨ If you’re an automation engineer looking at your next move, or a client needing specialist project support, Singapore is a place you should be considering. #Automation #LifeSciences #Pharma SGP Technology

72

2 Comments

"Hong Kong’s integration with the Greater Bay Area presents a unique chance to expand clinical trials, talent development, and patient access to cutting-edge therapies.” PharmaBoardroom spoke with Tony Cheng, Managing Director & GM, Hong Kong & Macau, Merck Healthcare, on how Merck is: - Building Hong Kong as a regional hub for clinical development - Investing in digital health and personalised medicine - Attracting and retaining local scientific talent - Ensuring faster access to innovative therapies for patients in Hong Kong and Macau This interview is part of our Hong Kong and Greater Bay Area Healthcare & Life Sciences Report 2025, showcasing how pharma leaders are advancing innovation and healthcare outcomes in the region. Read the full conversation here: https://lnkd.in/gRP3BYup

93

We’re pleased to share that Charles River Laboratories Singapore, a site specializing in QC microbiology testing and identification, is now officially FDA registered and operating in full compliance with Current Good Manufacturing Practices (cGMP). This milestone reflects our unwavering commitment to supporting our clients with the highest standards of safety, quality, and regulatory excellence, ultimately ensuring the integrity of the pharmaceuticals patients rely on every day. Learn more about our contract testing services: https://okt.to/2bh17R

132

2 Comments

Creador Bets Big on Indian Pharma with 7% Stake in La Renon Healthcare Pvt.Ltd. Kuala Lumpur-based private equity firm Creador has acquired a 7% stake in La Renon Healthcare Pvt.Ltd. for ₹800 crore. This investment values La Renon at nearly ₹11,000 crore, marking a significant milestone in the company’s rapid growth journey and reflecting robust investor confidence in India's pharmaceutical sector. Background of the Deal The new transaction builds on La Renon’s earlier funding successes and sharp valuation rise. Following the deal, the promoter family, led by Pankaj Singh, retains a controlling 66% stake, while private equity investors, including ChrysCapital, Peak XV Partners, A91 Partners, and Avendus, collectively hold a 34% stake. Specifically, the promoter family is selling about 5% of equity, with Peak XV offloading around 2% to accommodate the new investment. This is not Creador’s first foray into La Renon. In recent years, ChrysCapital acquired an 8% stake, valuing the company at ₹6,500 crore in 2024. Avendus Future Leaders Fund also participated in minority investments during this period. The current deal values La Renon at its highest point ever, underscoring the growth narrative backed by strong fundamentals and an expanding market presence. https://lnkd.in/gB4va5em via MedicinMan - Amplifying Healthcare Voices

60

1 Comment